Abstract: Quality of life (QOL) has been defined as “the individual’s perception of their position in life, in the context of the cultural and value systems in which they live and in relation to their goals, expectations, standards and concerns.”1 It is an abstract multidimensional construct reflecting the physical, psychological, and social aspects of an individual’s condition complementing the concept of health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.”2 Many dermatologic conditions pose minimal threat to patients in terms of mortality but have the capacity to significantly impinge upon a patient’s QOL. This is often because of the disfiguring nature of skin disease with its adverse impact on body image and succeeding burden on social function, which may be independent of clinical severity. Physical symptoms such as pain and itch can strongly affect QOL, and auxiliary considerations such as functional limitations, financial burden, and side effects of treatment all exert a detrimental effect on QOL. Accordingly, an assessment of QOL provides a suitable means to evaluate the impact of patients’ dermatosis on their well-being, and quantifying this impact has stemmed from a desire to evaluate outcomes of medical intervention.3 With the rise of QOL research and general qualitative inquiry in areas outside its traditional sociologic sphere, health care providers are increasingly looking toward semiqualitative measurement tools to assess and measure the impact of diseases within their patient population. Such measurements of QOL and burden of disease have multiple benefits, including